{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:04Z","timestamp":1792021624317,"version":"4.4.0"},"reference-count":150,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1080\/13543784.2026.2619605","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:46:06Z","timestamp":1771429566000},"page":"133-150","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Investigational agents targeting alarmins for asthma treatment: insights and progress from phase I and II trials"],"prefix":"10.1080","volume":"35","author":[{"given":"Maral","family":"Ranjbar","sequence":"first","affiliation":[{"name":"McMaster University","place":["Hamilton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane E.","family":"Whetstone","sequence":"additional","affiliation":[{"name":"McMaster University","place":["Hamilton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravneet K.","family":"Hansi","sequence":"additional","affiliation":[{"name":"McMaster University","place":["Hamilton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"McMaster University","place":["Hamilton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail M.","family":"Gauvreau","sequence":"additional","affiliation":[{"name":"McMaster University","place":["Hamilton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.02.011"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2024-0082WS"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-017-0735-9"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061342"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126402"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221212"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402175"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01595"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062211"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100355"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201545537"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni805"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.10.042"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.031"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607305104"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/76923"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.5.659"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1008271107"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/database\/bau007"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3489"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.06.024"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2000567"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12435"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1783242"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804106"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051135"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051745"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1048"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150402"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.03.039"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05485-x"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010107"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.05.007"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21589-2"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201041033"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2009.08.009"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700603"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-157818"},{"issue":"68","key":"e_1_3_4_41_1","first-page":"OA3652","article-title":"Proof of mechanism for an inhaled anti-TSLP fragment antibody, AZD8630\/AMG104, in a phase 1 study in healthy adults and asthma patients","volume":"64","author":"Scott IC","year":"2024","unstructured":"Scott IC, Kovacina K, Cardner M, et al. Proof of mechanism for an inhaled anti-TSLP fragment antibody, AZD8630\/AMG104, in a phase 1 study in healthy adults and asthma patients. Eur Respir J. 2024;64(suppl 68):OA3652.","journal-title":"Eur Respir J"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.05.003"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12552"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15609"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201576"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901575"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00243-6"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00474-9"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061675"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.03.043"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2817"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2005-0003OC"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.03.019"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449248"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201509-1751OC"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature16161"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11071105"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12558"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402895"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S286036"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102312"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01296-2021"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00226-5"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01679-2"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1400696"},{"issue":"68","key":"e_1_3_4_67_1","first-page":"OA1972","article-title":"A phase 1 study of SHR-1905, a long-acting anti-TSLP monoclonal antibody, in healthy subjects and patients with asthma","volume":"64","author":"Chen Q","year":"2024","unstructured":"Chen Q, Yu C, Zou Y, et al. A phase 1 study of SHR-1905, a long-acting anti-TSLP monoclonal antibody, in healthy subjects and patients with asthma. Eur Respir J. 2024;64(suppl 68):OA1972.","journal-title":"Eur Respir J"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1401"},{"key":"e_1_3_4_69_1","unstructured":"A multicentre randomized double-blind placebo-controlled parallel group phase 2 study to evaluate the efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05593250"},{"key":"e_1_3_4_70_1","unstructured":"Pharmacokinetics pharmacodynamics safety and preliminary efficacy of subcutaneous injection of SHR-1905 in adolescent asthmatic subjects - an open-label single-dose phase II clinical study. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06786455"},{"key":"e_1_3_4_71_1","unstructured":"A multicentre randomized double-blind placebo controlled dose finding parallel group phase 2 study of an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. [cited 2025 Sep 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06748053"},{"key":"e_1_3_4_72_1","unstructured":"A multicentre randomized double-blind placebo-controlled parallel group phase III study to evaluate the efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07098403"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.065"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00714-4"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6115"},{"key":"e_1_3_4_76_1","unstructured":"A multicenter randomized double-blind placebo-controlled phase II clinical trial to evaluate the efficacy and safety of TQC2731 injection in patients with poorly controlled severe asthma. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05472324"},{"key":"e_1_3_4_77_1","unstructured":"A multicenter randomized double-blind placebo-controlled phase III clinical trial to evaluate the efficacy and safety of TQC2731 injections in patients with poorly controlled severe asthma. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06829784"},{"key":"e_1_3_4_78_1","unstructured":"A randomized double-blind placebo-controlled phase II clinical study to evaluate the efficacy and safety of CM326 in subjects with moderate to severe asthma. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05774340"},{"key":"e_1_3_4_79_1","unstructured":"A phase 1 first in human randomized double-blind placebo-controlled single ascending dose and multiple ascending dose study to investigate the safety tolerability pharmacokinetics pharmacodynamics and immunogenicity of GB-0895 in adults with mild to moderate asthma or single dose in chronic obstructive pulmonary disease (COPD). [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07116889"},{"key":"e_1_3_4_80_1","unstructured":"Safety tolerability and pharmacokinetics of MG-ZG122 in a single subcutaneous injection in chinese healthy adult subjects: a single-center randomized double-blind placebo-controlled dose-increasing phase I clinical trial. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05659927"},{"key":"e_1_3_4_81_1","unstructured":"A randomized double-blind placebo-controlled phase II clinical trial of MG-ZG122 humanized monoclonal antibody injection in adult subjects with moderate-to-severe asthma to evaluate efficacy and safety. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07054034"},{"key":"e_1_3_4_82_1","unstructured":"A phase 1 randomized double-blind study to investigate the safety tolerability pharmacokinetics and bioavailability of NSI-8226 in healthy participants. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06640920"},{"key":"e_1_3_4_83_1","unstructured":"A phase 1 open-label study to investigate the safety tolerability and pharmacokinetics of two formulations of subcutaneously administered solrikitug in healthy Japanese and non-Japanese participants. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06868082"},{"key":"e_1_3_4_84_1","unstructured":"A phase 2 randomized double-blind placebo-controlled multiple dose-ranging study to assess the safety tolerability pharmacokinetics and pharmacodynamics of solrikitug in adult participants with asthma (RAINIER). [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06496607"},{"key":"e_1_3_4_85_1","unstructured":"A randomized double-blind placebo-controlled single-ascending-dose phase I clinical study in healthy Chinese subjects to evaluate the safety tolerability and pharmacokinetics of HBM9378 (SKB378) after subcutaneous administration. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05790694"},{"key":"e_1_3_4_86_1","unstructured":"A phase 2 randomized double-blind placebo-controlled study to evaluate the pharmacokinetics immunogenicity safety and efficacy of WIN378 in adult participants with moderate or severe asthma. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07120503"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01193-2022"},{"key":"e_1_3_4_88_1","first-page":"A1386","article-title":"Phase 1 safety and efficacy of AZD8630\/AMG 104 inhaled anti-TSLP in healthy volunteers and patients with asthma on medium-high dose inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) with elevated baseline fractional exhaled nitric oxide (FeNO) [Abstract]","volume":"209","author":"Doffman S","year":"2024","unstructured":"Doffman S, Dosanjh D, Sadiq MW, et al. Phase 1 safety and efficacy of AZD8630\/AMG 104 inhaled anti-TSLP in healthy volunteers and patients with asthma on medium-high dose inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) with elevated baseline fractional exhaled nitric oxide (FeNO) [Abstract]. Am J Respir Crit Care Med. 2024;209:A1386.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_4_89_1","unstructured":"A study to assess the safety pharmacokinetics and pharmacodynamics of AZD8630 administered once daily via inhalation for 2 weeks in adults with asthma on medium-to-high dose inhaled corticosteroids and long-acting beta-agonists. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06795906"},{"key":"e_1_3_4_90_1","unstructured":"A Phase 2b randomised double-blind placebo-controlled dose range-finding study to assess efficacy and safety of multiple dose levels of inhaled AZD8630 given once daily for 12 weeks in adults with uncontrolled asthma at risk of exacerbations (LEVANTE). [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06529419"},{"key":"e_1_3_4_91_1","first-page":"A6996","article-title":"A multiple ascending-dose study with verekitug, a novel antibody to the human thymic stromal lymphopoietin receptor, in adults with asthma [Abstract]","volume":"209","author":"Singh D","year":"2024","unstructured":"Singh D, Deykin A, Lloyd P, et al. A multiple ascending-dose study with verekitug, a novel antibody to the human thymic stromal lymphopoietin receptor, in adults with asthma [Abstract]. Am J Respir Crit Care Med. 2024;209:A6996.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_4_92_1","unstructured":"A phase 2 randomized double-blind placebo-controlled multi-center dose-ranging study to evaluate the efficacy and safety of verekitug (UPB-101) in adult participants with severe asthma (VALIANT). [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06196879"},{"key":"e_1_3_4_93_1","unstructured":"A long-term extension study to evaluate safety and efficacy of verekitug (UPB-101) in adult participants with severe asthma who completed the VALIANT trial (VALOUR). [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06966479"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00085-3"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13864"},{"key":"e_1_3_4_96_1","first-page":"A6816","article-title":"Targeting of tslp and IL-13 by the novel NANOBODY\u00ae molecule SAR443765 reduces FeNO in asthma following single dose exposure [Abstract]","volume":"207","author":"Deiteren A","year":"2023","unstructured":"Deiteren A, Krupka E, Imberdis K, et al. Targeting of tslp and IL-13 by the novel NANOBODY\u00ae molecule SAR443765 reduces FeNO in asthma following single dose exposure [Abstract]. Am J Respir Crit Care Med. 2023;207:A6816.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_4_97_1","unstructured":"A randomized double-blind placebo-controlled parallel-group dose ranging study to assess the efficacy safety and tolerability of subcutaneous lunsekimig in adult participants with moderate-to-severe asthma. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06102005"},{"key":"e_1_3_4_98_1","unstructured":"An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06609239"},{"key":"e_1_3_4_99_1","unstructured":"A randomized phase 2 double-blind placebo-controlled parallel-group 2-arm study to investigate the efficacy safety and tolerability of subcutaneous lunsekimig (SAR443765) in adult participants with high-risk asthma who are not currently eligible for biologic treatment. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06676319"},{"key":"e_1_3_4_100_1","unstructured":"A randomized double-blind placebo-controlled three-part phase 1a dose escalation clinical trial to assess the safety pharmacokinetics and pharmacodynamics of CDX-622 in healthy participants. [cited 2025 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06650761"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131347"},{"key":"e_1_3_4_102_1","unstructured":"Proof of concept study to investigate etokimab (ANB020) activity in adult participants with severe eosinophilic asthma. [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03469934"},{"key":"e_1_3_4_103_1","unstructured":"Efficacy safety and pharmacokinetic profile of etokimab (ANB020) in adult participants with moderate-to-severe atopic dermatitis (ATLAS). [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03533751"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax2945"},{"key":"e_1_3_4_105_1","unstructured":"Study of safety tolerability and pharmacokinetics of multiple ascending doses of REGN3500 in adults with moderate asthma. [cited 2025 Oct 1]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT02999711"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13157"},{"key":"e_1_3_4_107_1","unstructured":"Evaluation of SAR440340 and as combination therapy with dupilumab in moderate-to-severe asthma participants. [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03387852"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024257"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36642-y"},{"key":"e_1_3_4_110_1","unstructured":"Study to assess the efficacy and safety of MEDI3506 in adults with uncontrolled moderate-to-severe asthma (FRONTIER-3). [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04570657"},{"key":"e_1_3_4_111_1","unstructured":"Dose range finding study to assess efficacy and safety of tozorakimab in adults with uncontrolled asthma on medium-to-high dose inhaled corticosteroids (Umbriel). [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06932263"},{"key":"e_1_3_4_112_1","unstructured":"Efficacy and safety study of GSK3772847 in subjects with moderately severe asthma. [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03207243"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2022.07.002"},{"key":"e_1_3_4_114_1","unstructured":"Repeat dose study of GSK3772847 in participants with moderate to severe asthma with allergic fungal airway disease (AFAD). [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03393806"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281205"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70338"},{"key":"e_1_3_4_117_1","unstructured":"A study to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of AMG 282 in healthy subjects and subjects with chronic rhinosinusitis with nasal polyps. [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02170337"},{"key":"e_1_3_4_118_1","unstructured":"A first-in-human double blind single dose study in healthy subjects and subjects with mild atopic asthma. [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01928368"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.03.044"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201212-2318OC"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1495540"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2453162"},{"key":"e_1_3_4_123_1","unstructured":"A single-arm phase Ic clinical study of XKH001 injection in patients with allergic asthma after multiple doses. [cited 2025 Oct 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07070297"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002352"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1730"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1410700111"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201406-1039OC"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.051"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2023.07.002"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.039"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2024.12.001"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051615"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2010.03542.x"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014241108"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14196"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070406"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.10.020"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20122332"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01461-2024"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.03.005"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13806"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes14091721"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00475"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.02.016"},{"key":"e_1_3_4_145_1","unstructured":"A randomized double-blind placebo-controlled parallel-group dose-ranging study investigating the efficacy safety and pharmacokinetic profile of ANB020 administered to adult subjects with moderate-to-severe atopic dermatitis [Internet]. 2018. https:\/\/clinicaltrials.gov\/study\/NCT03533751"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201611-2234OC"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.05.031"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01973.x"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03496-6"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.119149"},{"key":"e_1_3_4_151_1","unstructured":"A 12-week multicenter randomized double-blind parallel-arm placebo-controlled study to assess the efficacy and safety of CSJ117 when added to existing asthma therapy in patients \u2265 18 years of age with severe uncontrolled asthma [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04410523"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704064"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2619605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:35:10Z","timestamp":1773221710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2619605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1080\/13543784.2026.2619605"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2619605","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}